Haemonetics Reports Q1 FY26 Earnings; Conference Call Scheduled for Aug. 7.
ByAinvest
Thursday, Aug 7, 2025 6:20 am ET1min read
HAE--
The results show a decrease in revenue of $321 million, a 4% organic revenue increase, and a 12.9% organic ex-CSL revenue increase. Earnings per diluted share stood at $0.70, with adjusted earnings per diluted share at $1.10. Cash flow from operating activities was $17 million, and free cash flow was $2 million. Gross margin was 59.8% in the first quarter of fiscal 2026 compared to 52.0% in the first quarter of fiscal 2025.
Operating expenses increased by $3.2 million or 2.4% compared to the first quarter of fiscal 2025, driven by increased investments in research and development. The income tax rate was 25% in the first quarter of fiscal 2026, compared to 18% in the first quarter of fiscal 2025.
Haemonetics reaffirmed its previous fiscal 2026 GAAP total revenue and organic revenue growth guidance. The company also reaffirmed its adjusted operating margin guidance, adjusted earnings per diluted share guidance, and free cash flow guidance.
The webcast and conference call will provide further insights into the company's performance and future plans. Investors and analysts are encouraged to participate and access the replay for detailed analysis.
References:
[1] https://www.stocktitan.net/news/HAE/haemonetics-1st-quarter-fiscal-year-2026-earnings-release-32i3x2nuiovt.html
[2] https://www.marketscreener.com/news/haemonetics-q1-2026-haemonetics-corporation-earnings-release-ce7c5edfdb88f321
• Haemonetics releases Q1 FY26 financial results online. • Conference call and webcast set for August 7, 2025. • Results available on Investor Relations website. • Live webcast accessible via Haemonetics' investor relations website.
Haemonetics Corporation (NYSE: HAE) has announced the availability of its first quarter fiscal year 2026 financial results on its Investor Relations website. The company will host a conference call and webcast with investors and analysts on August 7, 2025, at 8:00 a.m. ET to discuss the results. The conference call requires pre-registration, and participants are recommended to join 10 minutes before the event. A replay of the conference call and webcast will be accessible for one year starting from August 7, 2025, at 11:00 a.m. ET.The results show a decrease in revenue of $321 million, a 4% organic revenue increase, and a 12.9% organic ex-CSL revenue increase. Earnings per diluted share stood at $0.70, with adjusted earnings per diluted share at $1.10. Cash flow from operating activities was $17 million, and free cash flow was $2 million. Gross margin was 59.8% in the first quarter of fiscal 2026 compared to 52.0% in the first quarter of fiscal 2025.
Operating expenses increased by $3.2 million or 2.4% compared to the first quarter of fiscal 2025, driven by increased investments in research and development. The income tax rate was 25% in the first quarter of fiscal 2026, compared to 18% in the first quarter of fiscal 2025.
Haemonetics reaffirmed its previous fiscal 2026 GAAP total revenue and organic revenue growth guidance. The company also reaffirmed its adjusted operating margin guidance, adjusted earnings per diluted share guidance, and free cash flow guidance.
The webcast and conference call will provide further insights into the company's performance and future plans. Investors and analysts are encouraged to participate and access the replay for detailed analysis.
References:
[1] https://www.stocktitan.net/news/HAE/haemonetics-1st-quarter-fiscal-year-2026-earnings-release-32i3x2nuiovt.html
[2] https://www.marketscreener.com/news/haemonetics-q1-2026-haemonetics-corporation-earnings-release-ce7c5edfdb88f321
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet